In the BioHarmony Drug Report Database
Palivizumab
Synagis (palivizumab) is an antibody pharmaceutical. Palivizumab was first approved as Synagis on 1998-06-19. It is used to treat respiratory syncytial virus infections in the USA. It has been approved in Europe to treat respiratory syncytial virus infections.
Trade Name
|
Synagis |
|---|---|
Common Name
|
palivizumab |
ChEMBL ID
|
CHEMBL1201586 |
Indication
|
respiratory syncytial virus infections |
Drug Class
|
Monoclonal antibodies: humanized, antiviral indications |
Image (chem structure or protein)
